Evidence map›Paper›PMID 24531716›Full record

ArticleOncogene2015

Modification of sialylation is associated with multidrug resistance in human acute myeloid leukemia.

H Ma, H Zhou, X Song, S Shi, J Zhang, L Jia

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 69 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. EarlyFrontiers in oncology · 2023
    Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. IntegratedCells · 2021
    Article
  17. The T/Tn-SpecificCancers · 2021
    Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

H MaDepartment of Medical Basic Laboratory, College of Laboratory Medicine, Dalian Medical University, Dalian, China.
H ZhouDepartment of Microbiology, Dalian Medical University, Dalian, China.
X SongDepartment of Medical Biology, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway.
S ShiDepartment of Medical Basic Laboratory, College of Laboratory Medicine, Dalian Medical University, Dalian, China.
J Zhang1] Department of Biochemistry, Institute of Glycobiology, Dalian Medical University, Dalian, China [2] Department of Biochemistry, School of Life Science and Medicine, Dalian University of Technology, Panjin, China.
L JiaDepartment of Medical Basic Laboratory, College of Laboratory Medicine, Dalian Medical University, Dalian, China.
Dalian Medical University · CNUiT The Arctic University of Norway · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aberrant cell surface sialylation patterns have been shown to correlate with tumor progression and metastasis. However, the role of sialylation regulation of cancer multidrug resistance (MDR) remains poorly understood. This study investigated sialylation in modification on MDR in acute myeloid leukemia (AML). Using mass spectrometry (MS) analysis, the composition profiling of sialylated N-glycans differed in three pairs of AML cell lines. Real-time PCR showed the differential expressional profiles of 20 sialyltransferase (ST) genes in the both AML cell lines and bone marrow mononuclear cells (BMMCs) of AML patients. The expression levels of ST3GAL5 and ST8SIA4 were detected, which were overexpressed in HL60 and HL60/adriamycin-resistant (ADR) cells. The altered levels of ST3GAL5 and ST8SIA4 were found in close association with the MDR phenotype changing of HL60 and HL60/ADR cells both in vitro and in vivo. Further data demonstrated that manipulation of these two genes' expression modulated the activity of phosphoinositide-3 kinase (PI3K)/Akt signaling pathway and its downstream target thus regulated the proportionally mutative expression of P-glycoprotein (P-gp) and MDR-related protein 1 (MRP1), both of which are known to be involved in MDR. Blocking the PI3K/Akt pathway by its specific inhibitor LY294002 or by Akt small interfering RNA resulted in the reduced chemosensitivity of HL60/ADR cells. Therefore, this study indicated that sialylation involved in the development of MDR of AML cells probably through ST3GAL5 or ST8SIA4 regulating the activity of PI3K/Akt signaling and the expression of P-gp and MRP1.

Indexed as

AdolescentAdultAgedATP-Binding Cassette, Sub-Family C ProteinsATP Binding Cassette Transporter, Subfamily B, Member 1ChildDrug Resistance, MultipleDrug Resistance, NeoplasmElafinFemaleGene Expression Regulation, NeoplasticHL-60 CellsHumansLeukemia, Myeloid, AcuteMaleMiddle AgedATP-Binding Cassette, Sub-Family C ProteinsATP Binding Cassette Transporter, Subfamily B, Member 1Elafinhaematoside synthetasemultidrug resistance-associated protein 1N-Acetylneuraminic AcidOncogene Protein v-aktPI3 protein, humanSialyltransferasesST8SIA4 protein, human

Identifiers

PMID24531716
OpenAlexW2028691804

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.